Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This...
Read moreCardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President...
Read moreAfter trending down in 2023, nickel prices climbed to a 10 month high in late May of this year. However,...
Read moreCyprium Metals Limited (ASX: CYM, OTC: CYPMF) (Cyprium or the Company) is pleased to announce the successful completion of Tranche...
Read moreThe US Federal Reserve announced an interest rate cut of 25 basis points on Wednesday (December 18), reducing its target...
Read moreOpawica Exploration (TSXV:OPW) is a Vancouver-based junior exploration company exploring and developing precious metal properties in Canada. Opawica’s flagship properties...
Read moreThe uranium market entered 2024 on strong footing after a year of significant price movement, as well as renewed attention...
Read moreMines and Money Miami, a key event for the mining industry, will take place on February 21-22, 2025, at the...
Read moreE-Power Resources Inc (CSE: EPR) (FSE: 8RO) (‘E-Power‘ or the ‘Company’) announces its intention to complete a non-brokered private placement...
Read moreThe United Nations has designated 2025 as the year of quantum science and technology, highlighting the profound impact that technological...
Read moreCopyright © 2024 taleoftrading.com | All Rights Reserved